Skip Nav Destination
Online First / Early View
Online first articles are accepted and edited, peer reviewed articles that are not yet assigned to volumes/issues, but are citable using DOI.
Online First
Research Articles November 7 2024
Standardizing Nutritional Care for Cancer Patients: Implementation and Evaluation of a Malnutrition Risk Screening
Viktoria Mathies; Anna P. Kipp; Jakob Hammersen; Karin G. Schrenk; Sebastian Scholl; Ulf Schnetzke; Andreas Hochhaus; Thomas Ernst
Oncol Res Treat (2024) https://doi.org/10.1159/000542460
Research Articles November 7 2024
Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care
Dominik Fugmann; Steffen Holsteg; Ralf Schäfer; Lars Kreuznacht; Daniela Speer; Günter Niegisch; Ulrike Dinger; André Karger
Oncol Res Treat (2024) https://doi.org/10.1159/000542458
Early View
Research Articles December 4 2024
Real-world survival outcomes in patients with different types of cancer managed with immune checkpoint inhibitors
Oncol Res Treat (2024) https://doi.org/10.1159/000542958
Letters December 3 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)
Maximilian Webendoerfer; Sophie Heinzen; Christine Sibbert; Marie-Elisabeth Leßmann; Cornelia Kropf-Sanchen; Michael Thomas; Amanda Tufman; Annalen Bleckmann; Marcel Wiesweg; Frank Griesinger; Lea Reitnauer; Tobias Raphael Overbeck
Oncol Res Treat (2024) https://doi.org/10.1159/000542957
Research Articles November 29 2024
Prognostic Significance of HER2 Positivity in Endometrium Cancer
Serhat Sekmek; Dogan Bayram; Irfan Karahan; Ismet Seven; Perihan Perkin; Kamil Hakan Muftuoglu; Oznur Bal; Bulent Yalcin; Dogan Uncu; Efnan Algin
Oncol Res Treat (2024) https://doi.org/10.1159/000542900
Research Articles November 28 2024
HER2(-low)-Expression on Circulating Tumor Cells (CTCs) and corresponding Metastatic Tissue in Metastatic Breast Cancer (MBC)
Lara M. Tretschock; Hannah Clemente; Katharina Smetanay; Carlo Fremd; Verena Thewes; Kathrin Haßdenteufel; Anna S. Scholz; Klaus Pantel; Sabine Riethdorf; Andreas Trumpp; Andreas Schneeweiss; Laura Michel; Thomas M. Deutsch
Oncol Res Treat (2024) https://doi.org/10.1159/000542830
Research Articles November 27 2024
Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany between 2015–2021
Antje Mevius; Johanna Lutter; Florian M. Karl; Liam Tuffy; Fabienne Schochter; Andreas Fuchs; Thomas Wilke
Oncol Res Treat (2024) https://doi.org/10.1159/000542773
Review Articles November 19 2024
Survivorship in CAR T-cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse Mortality
Oncol Res Treat (2024) https://doi.org/10.1159/000542631
Research Articles November 15 2024
Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany - Final results of the phase 2 multicohort INGE-B trial
Manfred Welslau; Karin Potthoff; Matthias Zaiss; Lothar Müller; Cosima Brucker; Christoph Salat; Michael Untch; Johannes Meiler; Diana Lüftner; Anja Welt; Steffen Dörfel; Volker Hagen; Alexander Stein; Rüdiger Liersch; Thomas Kuhn; Hans Ulrich Siebenbach; Gerlinde Bing; Corinne Vannier; Norbert Marschner; Katja Gratzke
Oncol Res Treat (2024) https://doi.org/10.1159/000542459
Research Articles November 11 2024
Sex-disaggregated analysis of central venous catheter-related bloodstream infections in patients with cancer
Enrico Schalk; Alva Seltmann; Boris Böll; Nicola Giesen; Judit Grans-Siebel; Oliver Kriege; Julia Lanznaster; Antrea Minti; Jan-Hendrik Naendrup; Julia Neitz; Jens Panse; Martin Schmidt-Hieber; Ruth Seggewiss-Bernhardt; Daniel Teschner; Philipp Weber; Kai Wille; Marie von Lilienfeld-Toal; Marcus Hentrich
Oncol Res Treat (2024) https://doi.org/10.1159/000542535
